<DOC>
	<DOC>NCT00106639</DOC>
	<brief_summary>This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.</brief_summary>
	<brief_title>A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Recipient of a firsttime kidney transplant Between the ages of 18 and 70 years, inclusive Recipient of any nonkidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690550</keyword>
	<keyword>kidney transplant</keyword>
</DOC>